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Background: There are dilemmas associated with the diagnosis and prognosis of prostate cancer which has lead
to over diagnosis and over treatment. Prediction tools have been developed to assist the treatment of the disease.
Methods: A retrospective review was performed of the Irish Prostate Cancer Research Consortium database and
603 patients were used in the study. Statistical models based on routinely used clinical variables were built using
logistic regression, random forests and k nearest neighbours to predict prostate cancer stage. The predictive ability
of the models was examined using discrimination metrics, calibration curves and clinical relevance, explored using
decision curve analysis. The N = 603 patients were then applied to the 2007 Partin table to compare the predictions
from the current gold standard in staging prediction to the models developed in this study.
Results: 30% of the study cohort had non organ-confined disease. The model built using logistic regression illustrated
the highest discrimination metrics (AUC = 0.622, Sens = 0.647, Spec = 0.601), best calibration and the most clinical
relevance based on decision curve analysis. This model also achieved higher discrimination than the 2007 Partin
table (ECE AUC = 0.572 & 0.509 for T1c and T2a respectively). However, even the best statistical model does not
accurately predict prostate cancer stage.
Conclusions: This study has illustrated the inability of the current clinical variables and the 2007 Partin table to
accurately predict prostate cancer stage. New biomarker features are urgently required to address the problem
clinician’s face in identifying the most appropriate treatment for their patients. This paper also demonstrated a
concise methodological approach to evaluate novel features or prediction models.
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Prostate cancer (PCa) is the most common cancer in
European and North American men, and the second most
common cause of male cancer deaths [1]. There are
dilemmas associated with the diagnosis and prognosis
of PCa which has lead to the over diagnosis and over
treatment of the disease [2]. However, new treatments
such as active surveillance are being introduced to
overcome these issues [3-6].
Prediction tools for PCa have been developed to assist
in the accurate diagnosis and treatment of the disease, and
address a wide variety outcomes; e.g. the Partin tables
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reproduction in any medium, provided the ornomograms [12-14], D’Amico risk classification [15],
CAPRA score [16] and many others [17-19]. For the
prediction of stage at radical prostatectomy (RP), the
Partin tables not only represent the most common predic-
tion tool used by clinicians, but have also undergone
extensive validation in a number of cohorts [20-26]. The
Partin table uses clinical stage based on digital rectal exam
(DRE), Gleason score (GS) of the prostate needle biopsy
[27-31], and serum prostate specific antigen (PSA) to pre-
dict stage at RP. PCa stage indicates the extent or location
of the cancer, and can be categorized as; organ confined
(OC), extracapsular extension (ECE), seminal vesicle inva-
sion (SVI) and/or lymph node involvement (LNI). Non-
organ confined (NOC) disease represents any stage which
extends beyond the prostate organ, i.e. ECE, SVI or LNI.
While the Partin table is well used by clinicians, excluding
this, few other prediction tools are used in a clinical setting.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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models are ongoing. External validations which validate
and compare two or more models are particularly useful.
Chun et al. used this approach and compared five logistic
regression (LR) based nomograms with other LR based
models, namely look up table, classification and regression
tree, artificial neural networks and risk group stratification
[32]. However, each set of models being compared was
developed in different patient cohorts and different
outcomes were compared, i.e. nomogram for BCR and
classification and regression tree for BCR, nomogram
for stage and look up table for stage.
The Partin table was developed using multivariate logistic
regression (MLR), however it isn’t known whether other
statistical modelling techniques would have been more
accurate to use with this type data. By extending the
work of Chun et al. and Partin et al., the aim of this
study is to explore a number of classification techniques
rather than just LR, each predicting the same outcome
and developed and tested in one cohort of patients, using
the same variables as those used in the Partin tables.
We also aim to explore methods to evaluate prediction
models, such as discrimination and calibration metrics,
as well as decision curve analysis.
Methods
Study population
A retrospective review was performed of the Irish Prostate
Cancer Research Consortium (PCRC) database. The PCRC
was founded in 2003, and is a multi-disciplinary trans-
institutional collaboration. Patient samples were sourced
from four institutions; three tertiary referral centres and
one private hospital. Eight consultant urologists and four
distinct pathology departments are involved in the acqui-
sition and grading of prostatic tissue. Ethical approval was
awarded in each hospital (Mater Misericordiae University
Hospital, St James’s Hospital, Beaumont Hospital, Mater
Private Hospital). Written informed consent was obtained
from study participants. Inclusion criteria for this study
were availability of pre-operative serum PSA, trans-rectal
ultrasound guided needle biopsy Gleason Score [27-31],
clinical T stage using TNM staging [33] identified by DRE
and the corresponding RP pathology reports. All study
participants had pathologically confirmed prostatic adeno-
carcinoma. Between February 2002 and October 2011, data
relating to 705 patients who underwent RP was collected
through the PCRC. A total of 102 patients were excluded
due to benign prostatic hyperplasia (BPH) and missing
data. This left a total of 603 patients.
Clinical and pathological assessment
The clinical stage was stratified as T1c (DRE negative) or
T2 (DRE positive) [33]. Recording of the sub-stratification
of T2 was not available for the analysis. The Gleasonscoring system was used for needle biopsy grading [27-31].
RP specimens were assigned as organ confined (OC) if the
tumour can be felt on examination, but has not spread
outside the prostate, extra capsular extension (ECE) if the
tumour has spread through the prostatic capsule on one
or both sides, seminal vesicle invasion (SVI) if the tumour
has invaded one or both seminal vesicles and lymph node
involvement (LNI) if the pelvic lymph nodes exhibited
prostate cancer [33]. Patients were then re-stratified as
organ confined (OC) or non-organ confined (NOC), where
NOC represents any pathological stage which is not OC.
Statistical analysis
Patient information included pre-operative PSA, clinical
stage based on DRE, biopsy Gleason score (GS), age and
family history. Descriptive statistics focused on frequencies
and proportions for categorical variables. Means, medians,
and ranges were reported for continuous data and error
measures were reported as 95% confidence intervals (CI).
The parametric independent samples t-test and non-
parametric Mann Whitney U test were used to examine
the statistical significance of differences in means for
normal and non-normal data respectively. Chi-square
test was used to compare frequencies for categorical data.
Seven statistical and algorithmic classification techniques
were used to develop models to predict stage at RP. These
included logistic regression, linear discriminant analysis,
classification and regression trees, k nearest neighbours,
artificial neural networks, support vector machines and
random forests. The objective of a classification model is
to classify patients in two or more groups based on a pre-
dicted outcome associated with each patient. On examin-
ation of the individual model fit for each of the seven
classification techniques, three models were chosen for
further analysis and model evaluation: logistic regression
[34], random forests [35] and k nearest neighbours [36].
The data was prepared for modelling using 5-fold cross
validation (Figure 1). 5-fold cross validation involves
randomly dividing the data into five evenly sized subgroups.
Each group is called a fold. A model is then constructed
using the data from the first four folds and applied to the
fifth group. The model building and validation process is
repeated five times with each fold of patients used once as
the validation set. This results in no patient being used to
both develop and test the model [37].
Model evaluation was carried out by examining calibra-
tion, discrimination and decision curve analysis [37-41].
The calibration of the models was measured using cali-
bration curves [39]. Calibration measures how close
the predicted probabilities are to actual probabilities. A
calibration curve plots predictions on the x-axis and the
true outcome on the y-axis. Due to the fact that the actual
outcomes are 0 and 1, Loess smoothing [42,43] was used
to estimate the observed probabilities of the outcome in
Figure 1 Illustration of 5-fold cross validation. The dataset is randomly split into five subgroups (called folds). Four folds are merged together
to form a training dataset. The 5th fold is used as the testing dataset. This process is then repeated five times.
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ability of the models were compared by formulation of
sensitivity [44], specificity [44], positive predictive value
(PPV) [45], negative predictive value (NPV) [45], Youden
index [46,47], Brier score [48] and area under the curve
(AUC) values [49,50]. The discriminate ability of a model
measures how well the model discriminates between
patients with and without the outcome. The AUC value
provides us with a probability that the model will correctly
identify which of two individuals with different outcomes
actually has the disease.
However, there has been much criticism of the AUC
value in the last number of years [51,52]. This is due to the
fact that patient’s do not present to a clinician’s office in
pairs, one of whom has NOC disease and the other with
OC disease. There is also concern regarding what the
necessary AUC value should be for a model to be consid-
ered ‘clinically useful’. To overcome these issues, decision
curve analysis was used to measure the clinical relevance
of the three models [37,40,41]. Decision curve analysis is a
method for evaluating and comparing prediction models
that incorporates clinical consequences. It is based on the
principle that the probability at which a physician would
advise treatment is informative on how the physician and
patient weigh the harms of false-positive results in com-
parison with the harms of false-negative results. This
probability is referred to as the threshold probability
(Pt). This threshold probability (Pt) can then be used to











ð1ÞPlotting net benefit against threshold probability results
the ‘decision curve’. The decision curve gives the expected
net benefit per patient relative to assuming all patients
have OC disease, the expected benefit associated with
assuming all patients have NOC and the expected benefit
associated with using the classification model. The inter-
pretation of net benefit is the model with the highest net
benefit should be chosen.
The patient’s clinical data was also applied to the 2007
Partin table for ECE [7] in order to evaluate how well
this prediction tool can predict stage at RP compared to
the three classification models developed in this study.
The predictions from the Partin tables were measured for
discrimination.
Statistical analysis was performed using R software,
version 2.14.0 with the following packages: ‘car’, ‘boot’,
‘rpart’, ‘randomForest’, ‘class’, ‘e1071’, ‘MASS’, ‘nnet’, ‘ROCR’,
‘pROC’, ‘Hmisc’, ‘rms’, ‘gmodels’, ‘gplots’, ‘epicalc’.
Results
The clinical and pathological characteristics of the N = 603
PCRC patient cohort are given in Table 1. Average patient
age was 61 (C.I: 60.4, 61.6) years (median 62, range 42–74).
Average PSA value was 7.96 (C.I: 7.57, 8.26) ng/ml (median
7.0, range 0.7-40). Most patients had clinical stage T1c
(44.3%), biopsy Gleason score 6 (37.1%) and prostatectomy
Gleason score 3 + 4 (39.3%). 54.9% had no family history of
cancer, 20.1% had a history of cancer (excluding PCa) in
the family and 25.0% had a family history of PCa. Most
patients, 70%, had OC disease while the remaining 30%
had NOC disease (Table 1). Of the NOC patients, 19% had
ECE, 8% SVI and 3% LNI. Patients with NOC disease had
a higher average PSA than OC patients (Mean: 8.6 ng/ml
vs. 7.6 ng/ml), higher biopsy Gleason score (GS8: 9.9% vs.
Table 1 Prostate cancer research consortium patient
cohort characteristics
PCRC data OC NOC p
(n = 603) (n = 427) (n = 176)
Age (y)
Mean (Median) 61.1 (62) 60.7 (61) 62.2 (63) 0.01
Range 42-74 42-74 42-74
Family history (%)
PCa history 151 (25.0) 107 (25.1) 46 (28.9) 0.70
Ca history 121 (20.1) 85 (19.9) 26 (16.4)
No history 331 (54.9) 235 (55.0) 87 (54.7)
Clinical stage, DRE (%)
T1c 267 (44.3) 188 (44.1) 79(44.9) 0.69
T2a 144 (23.9) 99 (23.1) 45 (25.6)
Not reported 192(31.8) 140 (32.8) 52 (39.5)
PSA (ng/ml)
Mean (Median) 7.96 (7.0) 7.6 (6.7) 8.6 (7.5) 0.02
Range 0.7 – 40 0.7 – 40 2.1 – 36
Biopsy GS (%)
5 96 (17.4) 77 (19.7) 19 (11.8) P < 0.001
6 205 (37.1) 163 (41.7) 42 (26.1)
3 + 4 = 7 153 (27.7) 103 (26.3) 50 (31.1)
4 + 3 = 7 46 (8.3) 22 (5.7) 24 (14.9)
8 34 (6.2) 18 (4.6) 16 (9.9)
9 18 (3.3) 8 (2.0) 10 (6.2)
Prostatectomy GS (%)
5 59 (9.8) 46 (10.8) 13 (7.4) P < 0.001
6 151 (25.0) 125 (29.2) 26 (14.8)
3 + 4 = 7 237 (39.3) 181 (42.4) 56 (31.8)
4 + 3 = 7 90 (14.9) 44 (10.3) 46 (26.1)
8 42 (7.0) 20 (4.7) 22 (12.5)
9 24 (4.0) 11 (2.6) 13 (7.4)
Pathological stage
OC 427 (70) 427 (70) -
ECE 111 (19) - 111 (63)
SVI 47 (8) - 47 (27)
LNI 18 (3) - 18 (10)
Boyce et al. BMC Medical Informatics and Decision Making 2013, 13:126 Page 4 of 10
http://www.biomedcentral.com/1472-6947/13/1264.6%), higher prostatectomy Gleason score (GS8: 12.5% vs.
4.7%) and were older (Mean: 62.2 years vs. 60.7 years).
These findings were all statistically significant at the
P < 0.05 level. No significant differences were recorded
according to stage at RP for clinical stage or family history
(both P > 0.05).
The Gleason score based on TRUS biopsy and the
Gleason score recorded by pathology at RP were compared
to measure the percentage of Gleason score upgrading or
downgrading (Table 2). 52.9% of patients experience noGleason upgrading or downgrading, i.e. the results of their
TRUS biopsy were accurate. However, of the remaining
47.1% of patients, 34.1% experienced upgrading and 13.0%
experienced down grading of their Gleason score. This
indicates a 47% grading error based on TRUS biopsy.
Seven prediction models were developed using logistic
regression, linear discriminant analysis, classification and
regression trees, k nearest neighbours, artificial neural
networks, support vector machines and random forests.
On examination of the individual model fit for each
classification technique, the linear discriminant analysis,
classification and regression trees, artificial neural networks
and support vector machines models were excluded as
these classification techniques were deemed inferior in
this study. This resulted in three prediction models; a
model developed using logistic regression, a model devel-
oped using random forests and a model developed using k
nearest neighbours. Each of these models contains the
same predictor variables (PSA, clinical stage and biopsy
GS) and have all been developed using the same 5-fold
cross validation approach.
The discriminate ability of the three models was mea-
sured using discrimination metrics including sensitivity,
specificity, Youden index, positive predictive value (PPV),
negative predictive value (NPV), Brier score and AUC
values (Table 3). The logistic regression (LR) model
illustrates a sensitivity of 0.647 and a specificity of 0.601,
indicating that this model correctly identified 64.7% of
patients who had NOC disease and 60.1% of patients who
had OC disease, i.e. the model discriminates between both
NOC patients and OC patients to the same ability. How-
ever, these values for sensitivity and specificity, although
high relative to the other results in Table 3, are low based
on the fact that a perfect model would achieve a sensitivity
and specificity of 1. The Youden index for the LR model is
calculated as a summation of the sensitivity and specificity
minus 1; therefore due to the fact that both the sensitivity
and specificity are reasonably good, the Youden index for
this model (0.248) is reasonably good relative to the others
in Table 3. The Youden index is a useful metric when
there is no preference between sensitivity and specificity.
The LR model had a PPV of 0.495 and NPV of 0.800,
indicating that 49.5% of patients in the sample who
were predicted as being NOC by the model actually had
NOC disease and 80% of patients who were predicted as
being OC actually had OC disease. It should be noted
that, unlike sensitivity and specificity, NPV and PPV are
affected by the prevalence of disease in the sample. In
this study, the prevalence of having NOC disease is 30%
and of having OC disease is 70% (Table 1). When the
prevalence is low the PPV will be low, regardless of the
sensitivity and specificity. The Brier score for the LR model
is 0.173. The maximum Brier score for a model with a
prevalence of 30% is approximately 0.21. A model with a
Table 2 Percentage of Gleason score upgrading or downgrading
Biopsy GS
N (%) ≤6 7 (3 + 4) 7 (4 + 3) 8 9-10 Total
N 301 153 46 34 18 552
Decrease in GS 0 23 (15.1) 15 (32.6) 25 (73.5) 9 (50.0) 72 (13.0)
No change 170 (56.5) 92 (60.1) 16 (34.8) 5 (14.7) 9 (50.0) 292 (52.9)
Increase in GS 131 (43.5) 38 (24.8) 15 (32.6) 4 (11.8) 0 188 (34.1)
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between the predicted probabilities and the actual outcome.
The AUC value for the LR model is 0.622, which is reason-
ably good, but an AUC of 0.70 and above would be the
minimum required to consider a model useful for clinical
application. When comparing the LR model AUC with
those from the other classification models and clinical
variables in isolation (Table 3), the AUC of 0.622 for the
LR model is the highest. This is closely followed by biopsy
Gleason score (AUC = 0.618, Sens = 0.623, Spec = 0.613,
PPV = 0.396, NPV = 0.799, Brier = 0.179). These results
would indicate that biopsy Gleason score is by far the
individual predictor variable with the highest discriminate
ability. The integration of biopsy Gleason score with the
other clinical variables into a LR model improves the
ability to predict PCa stage at RP, but this improvement
is minimal, highlighting the strength of biopsy Gleason
score alone. Neither the random forests (RF) model
(AUC = 0.605, Sens = 0.673, Spec = 0.457, PPV = 0.339,
NPV = 0.771, Brier = 0.206) nor the K nearest neighbours
(kNN) model (AUC = 0.570, Sens = 0.673, Spec = 0.457,
PPV = 0.339, NPV = 0.771, Brier = 0.215) achieve better
overall discrimination than biopsy Gleason score alone or
the LR model.
The discrimination of the 2007 Partin table was also
measured (Figure 2). It should be noted that the Partin
tables predict four stages at RP (OC, ECE, SVI and LNI),
whereas the models developed in this study predict NOC
disease, where NOC is made up of ECE, SVI and LNI.
The majority of the NOC patients are made up of ECE,
therefore the most appropriate Partin table prediction to
look at in comparison to this study is the ECE predictions.
The 2007 Partin table can predict ECE with an AUC valueTable 3 Discrimination of prediction models and individual cl
Logistic regression Random forests K nearest n
Sens 0.647 0.477 0.673
Spec 0.601 0.714 0.457
Youden 0.234 0.192 0.129
PPV 0.495 0.410 0.339
NPV 0.800 0.767 0.771
Brier 0.173 0.206 0.215
AUC 0.622 0.605 0.570of 0.572 for patients with clinical stage T1c (Figure 2a)
and 0.509 for patients with clinical stage T2a (Figure 2b).
The calibration of each model was graphically measured
by formulation of calibration curves (Figure 3a-f ). The
blue line represents the fit based on Loess smoothing. A
model is well calibrated if the predicted probabilities or
Loess smoothing fit (blue line) lie along the 45° line.
Deviations away from this indicate mis–calibration. The
error bars represent the 95% confidence interval for
the predicted probabilities. The LR model (Figure 3a)
is well-calibrated, although there appears to be very
slight deviations from the 45° line at the very low and very
high predicted probabilities, indicating that some of the
lower predicted probabilities may slightly under estimate
the true outcome and some of the higher predicted
probabilities may slightly over-predict the true probability
of the patient, but it should be noted that these deviations
are minimal. The RF and kNN models illustrate some
mis-calibration (Figure 3b-3c), indicating that the pre-
dicted probabilities for these models deviate from the
true patient probability. Biopsy Gleason score (Figure 3d)
is reasonably well-calibrated; although some of the error
bars at predicted probabilities of approx 0.4 and 0.5 do
not conform to Loess smoothing. PSA is reasonably
calibrated (Figure 3e) although some clear over-prediction
is occurring at higher probabilities based on Loess
smoothing. The error bars indicate that the actua prob-
abilities are well calibrated. The calibration curve for
clinical stage (Figure 3f) illustrates how narrow the band
of predicted probabilities is for the model built based on
clinical stage (DRE) alone. The predicted probabilities vary
between approx 0.25 and 0.35. Based on this it is difficult
to examine the shape of the calibration of the error bars,inical variables








Figure 2 Predictions from the 2007 Partin tables. The patient’s data was applied to the 2007 (a) T1c and (b) T2a Partin tables and the
discriminate ability measured using ROC curves and AUC values. The AUC values of the ECE predictions are lower than those of the logistic
regression model developed in this study.
Figure 3 Calibration curves which illustrate predicted probabilities on the x-axis and the actual outcome on the y-axis. In this case the
outcome is a binary variable hence Loess smoothing (blue line) was used to estimate the actual outcomes for (a) logistic regression model, (b)
random forests model, (c) k nearest neighbours model, (d) biopsy Gleason score, (e) PSA and (f) clinical stage.
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to be mis-calibrated but this may in fact be due to the
narrowness of the range of predicted probabilities. Regard-
less of the fact that the predicted probability calibration
based on the error bars looks reasonably good, the narrow
range of the predicted probabilities indicates the weakness
of the clinical stage model and this has also been shown in
previous results (Table 3).
The results of decision curve analysis are compared by
means of decision curves (Figure 4), with separate decision
curves for the classification models (Figure 4a) and the
independent clinical variables in isolation (Figure 4b).
For both figures, the straight black line at y = 0 represents
the decision curve for the strategy of treating no patients
for NOC disease and the grey line represents the decision
curve for the strategy of treating all patients for NOC
disease. The LR model is superior to the RF and kNN
models as it has the highest net benefit at the majority
of threshold probabilities along the x-axis (Figure 4a).
From the same figure, it is also clear that the LR model is
well calibrated: for the majority of threshold probabilities,
the model never does worse than treating everyone (grey
line) and treating no one (thin black line at net benefit = 0),
unlike the other two models (RF and kNN), again illus-
trating that LR is the superior model in terms of dis-
crimination, calibration and now also clinical relevance.
An advantage of decision curves is the ability to identify
the range of probabilities at which a model will be clinically
relevant. For example, a clinician could input a new
patient’s clinical information into the model based on LR
and calculate their predicted probability. The clinicianFigure 4 Decision curves for (a) logistic regression model, random fo
Gleason score, PSA and clinical stage. In each decision curve the solid, t
grey line represents assuming everyone has NOC PCa.would then refer to the decision curve and find the
predicted probability along the x-axis and identify
which prediction model has the highest net benefit at
that point. If the LR model does not have the highest
net benefit at that point, the LR model is not the most
appropriate to use for this patient and an alternative
(the model with the highest net benefit at that point)
should be used instead. The RF and kNN models show
mis-calibration at threshold probabilities between 0-25%.
The range of threshold probabilities that these two
models would be useful at is between 25-30%, however,
at these threshold probabilities, the LR model would
be the optimal prediction tool to use. The range of
threshold probabilities that the LR model would be
useful at is between 0-50%, and although there is a
slight dip at approx 20%, at the majority of threshold
probabilities this model has the highest net benefit. Of
the individual clinical variables (Figure 4b), the Gleason
score model appears to be the optimal model at thresh-
old probabilities of 25% and above, below which the
PSA model appears to be have a slightly higher net
benefit. All of the models based on clinical variables in
isolation appear to be reasonably well calibrated (except
for clinical stage) as they are never worse than treating
everyone and treating no one. Clinical stage (thick blue
line) shows clear mis-calibration due to the fact that at
threshold probabilities between approx 26-31%, the model
is worse than treating everyone and this model also
appears to be poorly discriminative due to the fact that
between threshold probabilities of 30-35%, the model
is worse than treating no one.rests model and k nearest neighbours model and (b) biopsy
hin black line represents assuming no one has NOC PCa and the thin
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70% of patients had OC disease while the remaining 30%
had NOC disease (Table 1). This represents a 30% staging
error, as the entire study cohort were assumed to have OC
disease and hence underwent RP. 47.1% of patient’s biopsy
Gleason score was an incorrect estimate of their true
Gleason score at RP, indicating that only 52.9% of patients
did not experience an upgrading or downgrading of their
Gleason score. Our group had previously shown a 42%
Gleason score error between biopsy and RP in a smaller
sample (N = 206) of the same patient cohort [24]. This level
of upgrading or downgrading (42%) has been illustrated in
other studies [53]. It was difficult to ascertain published
figures for Gleason score upgrading or downgrading for the
last number of years, particularly studies with a reasonably
large sample size such as this one hence the result that
47.1% of patients experienced upgrading or downgrading
of their biopsy Gleason score at RP is a significant finding
of the paper.
The inclusion of the three clinical predictor variables
into a statistical classification model provided a minimal
improvement in predictive ability (discrimination, cali-
bration and clinical relevance) compared to the model
based on Gleason score in isolation, however, it was an
improvement none-the-less. It is obvious that the statistical
classification model is a welcome addition to PCa predic-
tion, even more so due to the fact that the future of
PCa staging is bound to contain complex new tests,
biomarkers or features. There is no alternative to inte-
grating multiple variables in a single prediction model
[52]. This study has illustrated LR as a superior modelling
technique.
Using the current clinical variables alone, excellent or
even good discrimination, calibration and clinical utility
will never be observed. Gleason score, PSA and clinical
stage based on DRE do not contain enough information
to accurately predict PCa stage at RP. New predictive
features are urgently required for the prediction of PCa
staging. The future of PCa prediction will likely involve
the integration of novel biomarkers with existing clinical
features. There are many ongoing biomarker discovery
and validation studies, both published and in progress
[54-63]. The modelling of such integrated data sets does
not present a problem. This study has illustrated LR is
as good and if not better than some of the newer more
complex classification techniques. This is due in part to
the fact that there are no complex relationships between
PCa variables which need to be allowed for in a statistical
model. The area which will require further, ongoing
research is around methods to evaluate a new predictive
marker/model. An initial framework to address this has
been implemented in this study, an approach which ex-
amined discrimination, calibration and clinical relevance,
based on previous work by Steyerberg et al. [39,64,65].Conclusion
This study has illustrated the inability of the current
clinical variables to accurately predict PCa stage. This is
in part due to the fact that the most predictive clinical
variable, Gleason score, over or underestimates the true
Gleason score at RP in 47.1% of patients. New biomarkers
or features are urgently required to address the problem
clinician’s face regarding accurately prognosticating
the appropriate treatment for PCa patients. This paper
has illustrated an approach which may be useful in the
evaluation of such novel biomarkers or features, or predic-
tion models in general.
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